A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|7|14|1408-1422

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.7, Iss.14, 2007-07, pp. : 1408-1422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protein kinase C inhibitors as novel anticancer drugs

By Jirousek Michael R   Goekjian Peter G  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 12, 2001-12 ,pp. : 2117-2140

Informa Healthcare

Access to resources Recommend Favorite

Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 4, 2009-04 ,pp. : 498-509

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

By  

Current Medicinal Chemistry, Vol. 20, Iss. 20, 2013-07 ,pp. : 2537-2551

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 5, 2012-05 ,pp. : 399-411

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas   Cherrington Julie M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite